Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Assets Average (2020 - 2025)

Tarsus Pharmaceuticals has reported Assets Average over the past 6 years, most recently at $548.4 million for Q4 2025.

  • Quarterly results put Assets Average at $548.4 million for Q4 2025, up 45.59% from a year ago — trailing twelve months through Dec 2025 was $548.4 million (up 45.59% YoY), and the annual figure for FY2025 was $469.6 million, up 46.18%.
  • Assets Average for Q4 2025 was $548.4 million at Tarsus Pharmaceuticals, up from $514.8 million in the prior quarter.
  • Over the last five years, Assets Average for TARS hit a ceiling of $548.4 million in Q4 2025 and a floor of $180.2 million in Q1 2022.
  • Median Assets Average over the past 5 years was $238.4 million (2022), compared with a mean of $298.8 million.
  • Biggest five-year swings in Assets Average: dropped 7.87% in 2023 and later skyrocketed 81.47% in 2024.
  • Tarsus Pharmaceuticals' Assets Average stood at $184.7 million in 2021, then increased by 25.73% to $232.2 million in 2022, then rose by 14.97% to $266.9 million in 2023, then soared by 41.11% to $376.6 million in 2024, then soared by 45.59% to $548.4 million in 2025.
  • The last three reported values for Assets Average were $548.4 million (Q4 2025), $514.8 million (Q3 2025), and $497.9 million (Q2 2025) per Business Quant data.